HE4: A new potential early biomarker for the recurrence of ovarian cancer

Tumor Biology

Volumn 31, Issue 2, 2010, Pages 113-119

  Anastasi, Emanuela ^a   Giovanna Marchei, Giulia ^a   Viggiani, Valentina ^a   Gennarini, Giuseppina ^a   Frati, Luigi ^a   Reale, Maria Gabriella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomarkers; CA125; HE4; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS SPECIFIC PROTEIN 4; MUCIN; PROTEIN HE4; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

EID: 77951252328     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-009-0015-y     Document Type: Article

References (27)

1. RF Ozols 2002 Recurrent ovarian cancer: evidence-based treatment J Clin Oncol. 20 1161 1163 11870155 (Pubitemid 34177419)
2. DM Parkin P Pisani J Ferlay 1999 Estimates of the worldwide incidence of 25 major cancers in 1990 Int J Cancer. 80 827 841 10.1002/(SICI)1097- 0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P 1:STN:280:DyaK1M7ntlajuw%3D%3D 10074914 (Pubitemid 29108856)
3. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin. 58 71 76 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
4. M Haries M Gore 2002 Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis Lancet Oncol. 3 529 536 10.1016/S1470- 2045(02)00846-X (Pubitemid 34993640)
5. S Pecorelli WT Creasman F Petterson JL Benedet JH Shepard 1988 FIGO annual report on the results of treatment in gynaecological cancer J Epidemiol Biostat. 3 75 102
6. DG Rosen L Wang JN Atkinson Y Yu KH Lu EP Diamandis I Hellerstrom SC Mok J Liu RC Bast Jr 2005 Potential markers that complement expression of CA125 in epithelial ovarian cancer Gynecol Oncol. 99 267 277 10.1016/j.ygyno.2005.06.040 1:CAS:528:DC%2BD2MXhtFKhsrfM 16061277 (Pubitemid 41502830)
7. RC Bast Jr D Badgwell LR Marquez D Rosen J Liu KA Baggerly EN Atkinson S Skates Z Zhang A Lokshin U Menoni I Jacobs K Lu 2005 New tumor markers: CA125 and beyond Int J Gynecol Cancer. 15 274 281 10.1111/j.1525-1438.2005.00441.x 16343244 (Pubitemid 43096594)
8. DX Chen PE Schwartz XG Li Z Yang 1988 Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic mass Obstet Gynecol. 72 23 27 1:STN:280:DyaL1c3kslerug%3D%3D 3164105
9. LR Medeiros DD Rosa MI da Rosa MC Bozzetti 2009 Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review Eur J Obstet Gynecol Reprod Biol. 142 99 05 1:CAS:528:DC%2BD1MXhs1ektL0%3D 18995946
10. C Tian M Markman R Zaino RF Ozols WP McGuire FM Muggia PG Rose D Spriggs DK Armstrong 2009 CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study Cancer. 115 1395 1403 10.1002/cncr.24152 1:CAS:528:DC%2BD1MXksF2ru7k%3D 19195045
11. N Urban M McIntosh M Andersen B Karlan 2003 Ovarian cancer screening Hematol Oncol Clin North Am. 17 989 905 10.1016/S0889-8588(03)00063-7 12959188 (Pubitemid 37022154)
12. C Kirchhoff 1998 Molecular characterization of epididymal proteins Rev Reprod. 3 86 85 10.1530/ror.0.0030086 1:CAS:528:DyaK1cXksVSjtLw%3D 9685187 (Pubitemid 28310280)
13. L Bingle V Singleton CD Bingle 2002 The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms Oncogene. 21 2768 2773 10.1038/sj.onc.1205363 1:CAS:528:DC%2BD38XjsVSms74%3D 11965550 (Pubitemid 34478335)
14. A Clauss H Lilja A Lundwall 2005 The evolution of a genetic locus encoding small serine proteinase inhibitors Biochem Biophys Res Commun. 333 383 389 10.1016/j.bbrc.2005.05.125 1:CAS:528:DC%2BD2MXlsVChtbw%3D 15950183 (Pubitemid 40848302)
15. A Clauss H Lilja A Lundwall 2002 A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein Biochem J. 368 233 242 10.1042/BJ20020869 1:CAS:528:DC%2BD38XosVOgu7o%3D 12206714 (Pubitemid 35463426)
16. R Drapkin HH von Horsten Y Lin SC Mok CP Crum WR Welch JL Hecht 2005 Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas Cancer Res. 65 2162 2169 10.1158/0008-5472.CAN-04-3924 1:CAS:528:DC%2BD2MXisFGgurY%3D 15781627 (Pubitemid 40490123)
17. MW McIntosh C Drescher B Karlan N Scholler N Urban KE Hellstrom I Hellstrom 2004 Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma Gynecol Oncol. 95 9 15 10.1016/j.ygyno.2004.07. 039 1:CAS:528:DC%2BD2cXnvVOisrk%3D 15385104 (Pubitemid 39286271)
18. MT Galgano GM Hampton HF Frierson Jr 2006 Comprehensive analysis of HE4 expression in normal and malignant human tissues Mod Pathol. 19 847 853 1:CAS:528:DC%2BD28Xkslels70%3D 16607372 (Pubitemid 43780455)
19. RG Moore AK Brown MC Miller S Kates WJ Allard MS Verch, et al. 2008 The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol. 108 402 408 10.1016/j.ygyno.2007.10. 017 1:CAS:528:DC%2BD1cXhtlOqtLo%3D 18061248 (Pubitemid 351174295)
20. RG Moore AK Brown CM Miller D Badgwell Z Lu J Allard CO Granai RC Bast Jr K Lu 2008 Utility of a novel serum tumor biomarker HE4 in patients with endometrial adenocarcinoma of the uterus Gynecol Oncol. 108 196 201 10.1016/j.ygyno.2008.04.002
21. JC Schink 1999 Current initial therapy of stage II and IV ovarian cancer: challenges for managed care Sem Oncol. 26 2 7 1:STN:280:DyaK1M7ntVWrtg%3D%3D
22. PG Moorman B Calingaert RT Palmieri ES Iversen RC Bentley S Halabi A Berchuck JM Schildkraut 2008 Hormonal risk factors for ovarian Am J Epidemiol. 167 1059 1069 10.1093/aje/kwn006 18303003 (Pubitemid 351601240)
23. MJ Duffy JM Bonfrer J Kulpa GJ Rustin G Soletormos TGC Tuxen ZM MK 2005 CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Int J Gynecol Cancer. 15 679 691 10.1111/j.1525-1438.2005.00130.x 1:STN:280:DC%2BD2Mrgt1Klsw%3D%3D 16174214 (Pubitemid 41783071)
24. I Hellerstrom KE Hellerstron 2008 SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other Adv Exp Med Biol. 622 15 121 10.1007/978-0-387-68969-2-2
25. Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Annual meeting of the ASCO 2008 Abstract.
26. JC Carroll C Cremin J Allanson SM Blaine H Dorman CA Gibbons, et al. 2008 Hereditary breast and ovarian cancers Can Fam Physician. 54 1691 1692 19074707 Review
27. PA Fasching S Gayther L Pearce JM Schildkraut E Goode F Thiel G Chenevix-Trench J Chang-Claude S Wang-Gohrke S Ramus P Pharoah A Berchuck OCAC (Ovarian Cancer Association Consortium) 2009 Role of genetic polymorphisms and ovarian cancer susceptibility Mol Oncol. 3 171 181 10.1016/j.molonc.2009.01.008 1:CAS:528:DC%2BC3cXjvFGisrk%3D 19383379